skip to Main Content

Preclinical Models Suggest Promise of CAR-NK Cell Treatment in Several Solid Tumors

Newsfeed image, light gray text on dark gray background
As researchers continue to improve on the efficacy and safety of chimeric antigen receptor (CAR) T-cell therapy in hematologic malignancies and work to bring the promise of the treatment to solid tumors, CAR natural killer (CAR-NK) cell treatment has shown early promise.

Previous research has suggested the efficacy of CAR-NK cells in hematological malignancies, and more recently, preclinical findings have raised the question of whether the type of treatment could be a viable, potentially more attractive option for solid tumors. Read more . . . .


Back To Top